Table 1.
Baseline characteristics of all enrolled patients with CHB according to the serum HBeAg level at the time of ETV treatment initiation
| All patients (n=44) | HBeAg-positive patients (n=25) | HBeAg-negative patients (n=19) | P-value | |
|---|---|---|---|---|
| Age, years | 44.6±11.4 | 44.6±13.0 | 44.7±9.3 | 0.969 |
| Male, n (%) | 28 (63.6) | 14 (56.0) | 14 (73.7) | 0.227 |
| BMI, kg/m2 | 23.5±2.7 | 23.6±3.2 | 23.5±2.2 | 0.936 |
| Diabetes, n (%) | 4 (9.1) | 1 (4.0) | 3 (15.8) | 0.178 |
| Hypertension, n (%) | 5 (11.4) | 2 (8.0) | 3 (15.8) | 0.420 |
| Cirrhosis, n (%) | 17 (38.6) | 10 (40.0) | 7 (36.8) | 0.831 |
| ALT, IU/mL | 260.7±423.9 | 202.0±197.6 | 338.0±605.1 | 0.297 |
| Bilirubin, mg/dL | 2.4±5.4 | 2.6±6.7 | 2.2±2.8 | 0.827 |
| Albumin, g/dL | 4.0±0.6 | 4.0±0.6 | 4.1±0.6 | 0.562 |
| Platelet count, ×109/L | 146.0±63.6 | 152.8±55.6 | 137.0±73.5 | 0.419 |
| Prothrombin time, INR | 1.2±0.3 | 1.2±0.4 | 1.1±0.2 | 0.559 |
| Creatinine, mg/dL | 0.9±0.2 | 0.8±0.2 | 0.9±0.2 | 0.227 |
| HBV DNA, log10 IU/mL | 6.8±1.3 | 7.2±1.0 | 6.2±1.5 | 0.011 |
Values are expressed as mean ± standard deviation or number (percent).
BMI, body mass index; ALT, alanine aminotransferase; INR, international normalized ratio; HBeAg, hepatitis B envelope antigen; HBV, hepatitis B virus.